Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 15/20 | 1.00 |
| ▸ | P2RY4 | P51582 | 10/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.96 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14396709 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL716499 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL5484468 | 0.94 | P2RY2 (0.88) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL2778525 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL76683 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL24414746 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL12671699 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL14976686 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL14406726 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL107380 | 0.91 | P2RY2 (0.94) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 771 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20220145295-A1 | ENZYMATIC RNA SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-12 | — | — | US | claimed |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | TRANSLATE BIO MA, INC. (US) | 2021-02-25 | — | — | US | claimed |
| EP-3737424-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | Translate Bio MA, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| US-20190175756-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175757-A1 | METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXIN | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175759-A1 | METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175758-A1 | METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175760-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| EP-3033424-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | Rana Therapeutics, Inc. (US) | 2016-06-22 | — | — | EP | claimed |
| EP-2978402-A1 | STABILIZED POLYRIBONUCLEOTIDE CODING FOR AN ELASTIC FIBROUS PROTEIN | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2016-02-03 | — | — | EP | claimed |
| WO-2015023975-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | WO | claimed |
| WO-2014154844-A1 | STABILIZED POLYRIBONUCLEOTIDE CODING FOR AN ELASTIC FIBROUS PROTEIN | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2014-10-02 | — | — | WO | claimed |
| US-20120195936-A1 | RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION | ETHRIS GMBH (DE) | 2012-08-02 | — | — | US | claimed |
| EP-2235177-B1 | METHOD FOR ENZYMATIC SYNTHESIS OF CHEMICALLY MODIFIED RNA | RIBOXX GMBH (DE) | 2012-07-18 | — | — | EP | claimed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | claimed |
| US-6184364-B1 | DEHYDRATING URIDINE TO FORM 2,2'-ANHYDROURIDINE, CONVERTING TO UNPROTECTED 2'-AZIDO-2'-DEOXYURIDINE, IODINATING TO FORM 5-IODO-2'-AZIDO, 2'-DEOXYURIDINE, THEN REDUCING TO 5-IODO, 2'-AMINO-2'-DEOXYURIDINE; SELEX LIGANDS | NEXSTAR PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | claimed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885P2RY6 3298/4885 |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | NSUN3, RNGTT, CSGALNACT1 | P2RY2 4737/4885P2RY4 4781/4885P2RY6 4211/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885P2RY6 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.